about
The potential for an enhanced role for MRI in radiation-therapy treatment planningManagement of skin toxicity during radiation therapy: a review of the evidenceCombined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).Mantle planning: report of the Australasian Radiation Oncology Lymphoma Group film survey and consensus guidelines.The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.Modern radiotherapy for modern surgeons: an update on radiation oncology.Frontiers of cancer care in Asia-Pacific region: cancer care in AustraliaA model for decision making for the use of radiotherapy in lung cancer.Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases.Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer careLung cancer patterns of care in south western Sydney, Australia.Estimation of an optimal radiotherapy utilization rate for breast carcinoma: a review of the evidence.Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence.Patterns of care study of brachytherapy in New South Wales: malignancies of the uterine corpus.Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence.Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva.Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma.Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I-lymphoma.Socio-demographic and other patient characteristics associated with time between colonoscopy and surgery, and choice of treatment centre for colorectal cancer: a retrospective cohort study.Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma.The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines.What should doctors know about cancer? Undergraduate medical education from a societal perspective.Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix: review of clinical practice guidelines and primary evidence.The varying role of the GP in the pathway between colonoscopy and surgery for colorectal cancer: a retrospective cohort studyAn evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer.Cost analysis of Gamma Knife stereotactic radiosurgery.Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines.Estimation of optimal brachytherapy utilization rate in the treatment of malignancies of the uterine corpus by a review of clinical practice guidelines and the primary evidence.An international review of patient safety measures in radiotherapy practice.'GAP' in radiotherapy services in Australia and New Zealand in 2009.Estimation of the optimal brachytherapy utilisation rate in the treatment of vaginal cancer and comparison with patterns of care.Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012.Evidence-based estimates of the demand for radiotherapy.Factors affecting the use of single-fraction radiotherapy for the palliation of bone metastases in Australia.A decade of investment in radiotherapy in New South Wales: why does the gap between optimal and actual persist?Estimation of the optimal number of radiotherapy fractions for breast cancer: A review of the evidence.Expanding global access to radiotherapy.Estimation of the optimal utilisation rates of radical prostatectomy, external beam radiotherapy and brachytherapy in the treatment of prostate cancer by a review of clinical practice guidelines.
P50
Q27691311-A1D550E5-BAF4-4101-AD66-D78318FBA657Q28286801-3EB6EC51-A0ED-4D2C-A38E-FEC0D1A39AEDQ31008298-552B015C-CF55-45BA-8091-C7909514D62CQ33927080-3B4F1BD3-7A25-45AE-8328-B4B554BC1049Q33984198-34731909-A07D-45D6-879C-ACE9F44B0E51Q34695431-163AA7CB-D1E1-4FAB-A805-272A98C20BA5Q34991701-8589CB39-C062-4DDB-8032-DE66DFFEB10DQ35062381-E3A366E3-F564-465C-B1FB-F9036B0DE543Q35188580-ED2B7DAA-36F0-4E85-8500-441534A2D8F7Q35344701-DACBBAF0-1EEC-4268-84D7-9296ABFC629CQ35536100-403217EB-E81D-478B-8F89-D0E9F6D6D7BFQ35570505-839E8816-ED50-4F34-9478-95993A382328Q35691667-0ED17F94-80DA-41FB-B4F9-332D40E1BF3CQ35843598-A294D44D-AE0A-461F-869D-87C36147B79DQ35860636-CEFCB790-2BE6-4D26-9584-187154D82CD3Q35860640-A8606998-08AE-4B93-BC3E-C091418E1417Q35860645-4CA44D33-6A23-48E5-8DC9-0DC1A635C069Q35981530-84D1AEB1-DDB3-444F-BC58-59303EB8BA8AQ35984890-E6EF7D16-EBCF-4887-BB81-BA4BD42D5474Q36008009-9835C1DD-E6C1-4E4A-8CA3-AD597AC17BD8Q36108794-A8A84C33-079C-4C06-83A6-0212EA829F4EQ36218369-CE61B74E-5ECC-4F83-9079-F9F89EB0F772Q36342392-4BD946B8-3E18-473D-A5AD-77FA657C5EE0Q36524712-68C5BFC8-B5C8-4D81-A041-CFC86DEE7605Q36655097-390F46F2-0FC9-47FB-86F0-24CE85D21E55Q36730014-14615CA8-868F-41C1-82D1-F7092A0850E4Q36776363-85AAF1E5-F5B8-41FC-9606-DFEF62D4A9A6Q36972094-33AB527B-4ECB-43A0-BFE8-54E01976C996Q37101512-7265D194-B971-4AD1-B2D7-6BBF735E8A7AQ37151498-31B751E4-BDB5-4C3F-8A07-AE6D22DBED88Q37460367-A6DFDFA7-B960-4728-B6D7-AB41F4A1CC30Q37769587-112AF666-1953-4820-AFBE-6375E386CAC8Q38033776-F57F37EE-AEE1-40D9-AA38-2C18032BD2ABQ38212196-3AAD942D-209A-4826-B851-9E90CD61062FQ38279405-1B842FDB-4333-48C5-A2B8-B674176D7366Q38297654-9FA9AB5D-D2C9-4D58-954A-4E72233773DDQ38421688-CDDD48CF-116D-4EBB-AA69-B7012D9A0658Q38566521-F188EC2B-55FC-4538-80D7-A80D4802F1B1Q38595280-F8119A19-5975-4096-8FA7-EDE9AEEC25EDQ38699681-FE64CE1C-8E26-4E28-B3A4-16642A83D0CA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael B. Barton
@ast
Michael B. Barton
@en
Michael B. Barton
@es
Michael B. Barton
@sl
مايكل بي. بارتون
@ar
type
label
Michael B. Barton
@ast
Michael B. Barton
@en
Michael B. Barton
@es
Michael B. Barton
@sl
مايكل بي. بارتون
@ar
prefLabel
Michael B. Barton
@ast
Michael B. Barton
@en
Michael B. Barton
@es
Michael B. Barton
@sl
مايكل بي. بارتون
@ar
P1053
M-7183-2015
P106
P1153
7202158595
P21
P31
P3829
P3835
michael-barton5
P496
0000-0003-0112-0680